UNSPSC 51191952: Thiamine nitrate

This classification denotes a b vitamin with the molecular formula C12H17N4OS.NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8K0I04919X, chemically known as 3-(4-amino-2-methylpyrimidyl-5-methyl)-4-methyl-5,beta-hydroxyethylthiazolium nitrate but more generally known as thiamine mononitrate, which bears US NIH Compound Identifier 10762. European Medicines Agency schedules Thiamine mononitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15528MIG.

Most nations, for tariff and trade purposes, schedule thiamine nitrate under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCO.[N+](=O)([O-])[O-].

UNSPSC 51191952 Thiamine nitrate, a Commodity code, reflects state and local procurement of pharmaceutical and chemical supply products for health care and municipal utility operations. Recent solicitations under this code show state and local governments buying generic pharmaceuticals, over-the-counter products, and water-treatment chemicals — a mix spanning health systems, cooperative purchasing alliances, and municipal utilities. The City of Meriden and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, are active buyers. Work solicited includes supply of pharmaceutical products distributed through authorized wholesalers to participating state and local facilities, and chemical commodities for water treatment operations, with vendors required to maintain cGMP and FDA compliance, supply-chain security certifications, and substantial insurance coverage including general liability of $1,000,000 to $5,000,000 depending on the scope.

Activity spans Connecticut and Minnesota with multistate reach through cooperative purchasing vehicles. The City of Meriden issued IFB B027-15 for sodium bisulfite chemical supply to its Water Pollution Control Facility with response due July 29, 2026, requiring performance and payment bonds and $1,000,000 to $2,000,000 in liability coverage. MMCAP issued RFP S1070000015802 on January 20, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with responses due March 26, 2026; the procurement evaluates pricing competitiveness at 75 percent weight, fixes administrative fees at 3 percent, and awards to multiple vendors based on therapeutic and member-specific needs. Contract terms run two years for new vendors with optional extensions through June 30, 2028 for incumbent responders.